We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in the coming years.
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
The first cell rejuvenation therapy is set to enter clinics, testing if aging cells can be reset to a younger, healthier ...
Meet 5 hot biotechs in Arizona, from Phoenix to Tucson, that have raised significant funding over the past decade.
Learn about Carbios' story, as the French biotech focused on recycling polyethylene terephthalate (PET), faces pressure after ...
The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.
February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...
Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results